Society of Cutaneous Oncology Society of Cutaneous Oncology
  • Journal
  • Journal Club
  • Research Forum
  • Community Highlights
  • About
    • About SoCO
    • Our Philosophy
    • History
  • Join Our Community

INTerpath-001

Society of Cutaneous Oncology

2026-11-20

SoCO Journal Club · November 20, 2026

INTerpath-001

After surgery for melanoma, how much does adding an individualized neoantigen vaccine to pembrolizumab improve the chance of remaining recurrence-free? In INTerpath-001, an estimated 12 more patients per 100 were alive and recurrence-free at two years with the combination than with pembrolizumab alone. For a patient already planning adjuvant PD-1 blockade, that comparison speaks directly to the decision at hand. For someone leaning toward surveillance, or someone we see before surgery, the decision is different.

The trialThe discussionPractice surveyCost and coverageWho joined
The paper we discussed

What did adding intismeran achieve?

Phase III trial · 2026

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma

Long GV and colleagues. New England Journal of Medicine, 2026.

Primary paper and supplement KEYNOTE-942 phase IIb report Five-year update
SoCO Journal Club, November 20, 2026. INTerpath-001: intismeran plus pembrolizumab for resected stage IIB–IV cutaneous melanoma.
After melanoma surgery, who would add intismeran?
Randomized, double-blind phase III trial1,137 participantsMedian follow-up 24.6 months

For our November Journal Club, SoCO members gathered to discuss INTerpath-001 with colleagues from Moderna and Merck who had worked on the trial. We walked through the paper figure by figure and discussed how we’d explain the results to patients at different stages of melanoma. Nikhil Khushalani opened with KEYNOTE-942, the randomized phase IIb study that prompted this larger trial.

INTerpath-001 enrolled patients with completely resected stage IIB–IV cutaneous melanoma. All participants were assigned to adjuvant pembrolizumab. Randomization allocated 757 to receive up to nine additional injections of intismeran autogene, an mRNA therapy designed from each patient’s tumor, and 380 to receive diluent placebo.

Estimated survival at 24 months
Intismeran + pembrolizumab (n = 757)Placebo + pembrolizumab (n = 380)
Recurrence-free survival
82.2%
70.0%
HR 0.58 (95% CI 0.45–0.75)
P < 0.001
Distant metastasis-free survival
88.5%
80.2%
HR 0.62 (95% CI 0.45–0.85)
P = 0.002

The bars show Kaplan–Meier estimates at two years. Hazard ratios summarize follow-up. Recurrence-free and distant metastasis-free survival met their prespecified testing thresholds. Overall survival was immature (HR 0.77, 95% CI 0.45–1.31).

Discussion highlights

What the room wrestled with

Why did the curves separate around six months?

Andrew Knight started with the part of Figure 1 that the overall hazard ratio obscures. The estimated RFS hazard ratio was 0.99 (95% CI 0.66–1.49) in the first six months and 0.42 (0.30–0.58) thereafter. Both groups could begin pembrolizumab while the individualized product was being made. The median time from randomization to first injection was 64 days for intismeran and 45 days for placebo.

Nikhil Khushalani asked what the delay says about the urgency of postoperative treatment. Michelle Brown raised the time needed to mount an immune response. Vishal Patel asked whether outcomes varied with time to the first dose. That analysis was unavailable. When Sanjay Chandrasekaran asked about apparent convergence late in follow-up, Li Fan pointed to the small numbers still at risk beyond 30 months.

At 24 months, estimated recurrence-free survival was 12.2 percentage points higher with intismeran plus pembrolizumab than with pembrolizumab alone. Over those first 24 months, patients in the combination group spent an average of 1.2 additional months alive without recurrence (95% CI, 0.4–2.1).

Who made it through screening?

Of 1,749 people screened, 1,137 reached randomization. Sameer Gupta asked where a personalized therapy could fall out of reach. Michelle Brown clarified that approximately 17% of people entering screening lacked tumor material that met the initial quality requirements. This occurred before randomization and manufacturing. The team could sometimes use another block, additional slides, or the original biopsy. Among randomized participants, the team described one product that missed the protocol’s manufacturing window.

Elizabeth Buchbinder raised a separate question about who was represented. Stage III included people with very different treatment options at diagnosis. The breakdown by clinically apparent nodal disease, microscopic nodal disease, and in-transit disease was unavailable during the discussion. Adewole Adamson cautioned against drawing geographic or other subgroup conclusions from estimates with few events and wide confidence intervals.

Could patients or their clinicians infer the assignment?

Vernon Sondak asked how the trial could reproduce the wait for an individualized product in the placebo arm. The study team described staggering the first placebo injection, masking the syringes, and separating preparation and administration roles. Suzanne Topalian asked what happened after the injection. Fever or an injection-site reaction might give someone a clue.

The Teams chat connected that possibility to investigator-assessed recurrence. The protocol scheduled imaging every 12 weeks through week 96, beginning at week 12. An equivocal finding still leaves room for judgment about additional imaging or biopsy. The group questioned whether suspected assignment might affect that judgment and whether a more reactogenic control would be ethical. The effect of any inadvertent unblinding remains uncertain.

What would establish that the selected antigens mattered?

Suzanne Topalian recognized the achievement of delivering individualized treatment across an international trial, then asked what the expanded T-cell clones actually recognized. Michael Wong asked how much of the effect might arise from the delivery platform. A diluent placebo answers the clinical question about adding the complete product. It leaves the contribution of the encoded neoantigens unresolved.

Suzanne Topalian and Michael Wong wanted functional evidence of recognition of the selected targets, including comparable analyses in patients receiving pembrolizumab alone. Laureen Ojalvo described ongoing analyses. Dmitri Grebennik also raised the ethical cost of exposing controls to an investigational formulation solely to mimic adverse effects.

How should we discuss the eight fatal adverse events?

Danielle Brazel and Karam Khaddour walked the group through the safety tables. Grade 3–5 adverse events of any cause occurred in 23.6% with the combination and 20.3% with placebo plus pembrolizumab. An adverse event led to discontinuation of at least one trial agent in 16.6% and 9.5%, respectively. Fever, injection-site symptoms, and flu-like reactions also mattered to patients receiving repeated injections.

The safety population included 755 patients in the combination arm and 380 controls. Eight fatal adverse events occurred in the former group and zero in the latter. Five occurred before the first intismeran dose, including both deaths investigators attributed to pembrolizumab. Investigators judged the three after intismeran dosing unrelated to either agent. Michael Wong emphasized how differently even a rare serious harm can weigh on someone who may already have been cured by surgery.

Does the result change what happens before surgery?

Suzanne Topalian compared the delayed separation here with the early separation in NADINA. Vernon Sondak pointed out that the two trials started their clocks at different times. NADINA enrolled people with macroscopic stage III disease before surgery, so its event-free survival analysis counted events that could prevent surgery. INTerpath-001 enrolled after complete resection. A patient who progressed before postoperative randomization could never enter its RFS analysis.

The distinction has an immediate clinical consequence. A patient referred with palpable, resectable nodes has a neoadjuvant option. A patient first seen after those nodes have been removed faces an adjuvant decision. Vernon Sondak closed by asking whether individualized therapy might have a role for patients left at high risk after an inadequate neoadjuvant response. The question remains open. NADINA trial

Pre-meeting survey

Where would clinicians add intismeran?

Before Journal Club, respondents described what patients with completely resected melanoma usually receive in their practice. In the same questionnaire, they chose what they expected patients would receive if pembrolizumab plus intismeran were approved, accessible and covered. Each bar shows one choice per respondent. Within each stage and BRAF group, both questions use the same respondents with two complete answers.

For BRAF wild-type stage IIIC, 23 of 23 respondents already favored systemic therapy, and 21 of 23 would choose the combination if available. For stage IIB, 18 of 23 selected surveillance under current practice and 16 of 23 would select it with access to the combination.

The initial BRAF-mutant scenario specified V600E/K. Later versions specified V600E. The figures pool responses across both wordings. Respondents could answer multiple stages and genotypes.

Current practiceWhat do patients typically receive now?
BRAF wild-typeUsual treatment after shared decision-making
SurveillanceAnti–PD-1 alone
StageShare of respondents selecting each treatmentPaired n
IIB
78%22%
Surveillance 18/23 (78.3%)PD-1 alone 5/23 (21.7%)
23
IIC
43%57%
Surveillance 10/23 (43.5%)PD-1 alone 13/23 (56.5%)
23
IIIA
74%26%
Surveillance 17/23 (73.9%)PD-1 alone 6/23 (26.1%)
23
IIIB
13%87%
Surveillance 3/23 (13.0%)PD-1 alone 20/23 (87.0%)
23
IIIC
100%
Surveillance 0/23 (0.0%)PD-1 alone 23/23 (100.0%)
23
IIID
100%
Surveillance 0/22 (0.0%)PD-1 alone 22/22 (100.0%)
22
IV resected
100%
Surveillance 0/22 (0.0%)PD-1 alone 22/22 (100.0%)
22
Current practiceWhat do patients typically receive now?
BRAF-mutantUsual treatment after shared decision-making
SurveillanceAnti–PD-1 aloneDabrafenib + trametinib
StageShare of respondents selecting each treatmentPaired n
IIB
78%22%
Surveillance 18/23 (78.3%)PD-1 alone 5/23 (21.7%)Dab/Tram 0/23 (0.0%)
23
IIC
48%52%
Surveillance 11/23 (47.8%)PD-1 alone 12/23 (52.2%)Dab/Tram 0/23 (0.0%)
23
IIIA
48%17%35%
Surveillance 11/23 (47.8%)PD-1 alone 4/23 (17.4%)Dab/Tram 8/23 (34.8%)
23
IIIB
61%35%
Surveillance 1/23 (4.3%)PD-1 alone 14/23 (60.9%)Dab/Tram 8/23 (34.8%)
23
IIIC
78%22%
Surveillance 0/23 (0.0%)PD-1 alone 18/23 (78.3%)Dab/Tram 5/23 (21.7%)
23
IIID
77%23%
Surveillance 0/22 (0.0%)PD-1 alone 17/22 (77.3%)Dab/Tram 5/22 (22.7%)
22
IV resected
95%
Surveillance 0/22 (0.0%)PD-1 alone 21/22 (95.5%)Dab/Tram 1/22 (4.5%)
22
Hypothetical practiceWhat would patients receive if the combination were available?
BRAF wild-typeAssuming approval, access and coverage
SurveillanceAnti–PD-1 alonePembrolizumab + intismeran
StageShare of respondents selecting each treatmentPaired n
IIB
70%26%
Surveillance 16/23 (69.6%)PD-1 alone 1/23 (4.3%)PD-1 + intismeran 6/23 (26.1%)
23
IIC
43%52%
Surveillance 10/23 (43.5%)PD-1 alone 1/23 (4.3%)PD-1 + intismeran 12/23 (52.2%)
23
IIIA
61%39%
Surveillance 14/23 (60.9%)PD-1 alone 0/23 (0.0%)PD-1 + intismeran 9/23 (39.1%)
23
IIIB
9%87%
Surveillance 1/23 (4.3%)PD-1 alone 2/23 (8.7%)PD-1 + intismeran 20/23 (87.0%)
23
IIIC
9%91%
Surveillance 0/23 (0.0%)PD-1 alone 2/23 (8.7%)PD-1 + intismeran 21/23 (91.3%)
23
IIID
9%91%
Surveillance 0/22 (0.0%)PD-1 alone 2/22 (9.1%)PD-1 + intismeran 20/22 (90.9%)
22
IV resected
14%86%
Surveillance 0/22 (0.0%)PD-1 alone 3/22 (13.6%)PD-1 + intismeran 19/22 (86.4%)
22
Hypothetical practiceWhat would patients receive if the combination were available?
BRAF-mutantAssuming approval, access and coverage
SurveillanceAnti–PD-1 aloneDabrafenib + trametinibPembrolizumab + intismeran
StageShare of respondents selecting each treatmentPaired n
IIB
70%30%
Surveillance 16/23 (69.6%)PD-1 alone 0/23 (0.0%)Dab/Tram 0/23 (0.0%)PD-1 + intismeran 7/23 (30.4%)
23
IIC
43%52%
Surveillance 10/23 (43.5%)PD-1 alone 1/23 (4.3%)Dab/Tram 0/23 (0.0%)PD-1 + intismeran 12/23 (52.2%)
23
IIIA
48%22%30%
Surveillance 11/23 (47.8%)PD-1 alone 0/23 (0.0%)Dab/Tram 5/23 (21.7%)PD-1 + intismeran 7/23 (30.4%)
23
IIIB
9%83%
Surveillance 1/23 (4.3%)PD-1 alone 1/23 (4.3%)Dab/Tram 2/23 (8.7%)PD-1 + intismeran 19/23 (82.6%)
23
IIIC
91%
Surveillance 0/23 (0.0%)PD-1 alone 1/23 (4.3%)Dab/Tram 1/23 (4.3%)PD-1 + intismeran 21/23 (91.3%)
23
IIID
9%86%
Surveillance 0/22 (0.0%)PD-1 alone 1/22 (4.5%)Dab/Tram 2/22 (9.1%)PD-1 + intismeran 19/22 (86.4%)
22
IV resected
9%91%
Surveillance 0/22 (0.0%)PD-1 alone 2/22 (9.1%)Dab/Tram 0/22 (0.0%)PD-1 + intismeran 20/22 (90.9%)
22
Compare expected combination use across BRAF groups
StageBRAF wild-typeBRAF-mutantIIB
6/23 (26.1%)
7/23 (30.4%)
IIC
12/23 (52.2%)
12/23 (52.2%)
IIIA
9/23 (39.1%)
7/23 (30.4%)
IIIB
20/23 (87.0%)
19/23 (82.6%)
IIIC
21/23 (91.3%)
21/23 (91.3%)
IIID
20/22 (90.9%)
19/22 (86.4%)
IV resected
19/22 (86.4%)
20/22 (90.9%)

Source · SoCO paired pre-meeting survey export dated 2026-11-21.

How much did choices change within each stage?

Each cell gives the percentage-point difference between hypothetical and usual practice. The final column counts respondents who selected a different option, including switches that canceled out in the overall distribution. The combination was offered only in the hypothetical question.

BRAF wild-type

Stage Surveillance PD-1 alone PD-1 + intismeran Changed choice
IIB −8.7 −17.4 +26.1 26.1%6/23
IIC 0.0 −52.2 +52.2 56.5%13/23
IIIA −13.0 −26.1 +39.1 39.1%9/23
IIIB −8.7 −78.3 +87.0 87.0%20/23
IIIC 0.0 −91.3 +91.3 91.3%21/23
IIID 0.0 −90.9 +90.9 90.9%20/22
IV resected 0.0 −86.4 +86.4 86.4%19/22

BRAF-mutant

Stage Surveillance PD-1 alone Dab/Tram PD-1 + intismeran Changed choice
IIB −8.7 −21.7 0.0 +30.4 34.8%8/23
IIC −4.3 −47.8 0.0 +52.2 56.5%13/23
IIIA 0.0 −17.4 −13.0 +30.4 34.8%8/23
IIIB 0.0 −56.5 −26.1 +82.6 82.6%19/23
IIIC 0.0 −73.9 −17.4 +91.3 91.3%21/23
IIID 0.0 −72.7 −13.6 +86.4 86.4%19/22
IV resected 0.0 −86.4 −4.5 +90.9 90.9%20/22

When the patient presents before surgery

The survey asked how clinicians would treat a fit patient with clinically apparent, resectable stage III melanoma who had received no prior systemic therapy. 24.0 respondents are represented in this question, which was added in later versions of the survey.

Neoadjuvant therapy first

Ipilimumab + nivolumab
21/24 (87.5%)
Pembrolizumab
1/24 (4.2%)

Surgery first

Then pembrolizumab + intismeran
0/24 (0.0%)
Then anti–PD-1 alone
0/24 (0.0%)

Other

Another strategy or clinical trial
0/24 (0.0%)
Outside clinical role
2/24 (8.3%)

Source · SoCO pre-meeting survey question summary.

What divided the room at stage IIIA?

Suzanne Topalian favored surveillance. Nikhil Khushalani would discuss treatment in light of the patient’s baseline risk and favored discussing targeted therapy for BRAF V600 disease. Vishal Patel described a patient who might reasonably choose surveillance but, once committed to treatment, would prefer the combination to PD-1 alone.

David Miller asked for the absolute benefit by substage. With only 50 and 32 stage IIIA patients in the two trial arms, precise estimates would be difficult. For BRAF-mutant disease, Nikhil Khushalani also asked how clinicians would weigh the mature experience with dabrafenib–trametinib. INTerpath-001 did not compare those two regimens directly.

Cost and coverage

What belongs in the value calculation?

Isaac Brownell asked how many lower-risk patients would need treatment to prevent one recurrence, and what that would cost. Vernon Sondak asked the other half of that question. What does it cost a patient and a health system to treat a distant recurrence, sometimes through several lines of therapy? Both questions depend on the patient’s absolute risk, the durability of benefit, and the consequences of treatment.

The premeeting survey asked how cost or coverage would influence recommendations, taking account of both out-of-pocket costs and overall treatment resources. It specified no price. The chat also raised how long therapy must continue for optimal benefit. INTerpath-001 evaluated the assigned regimen as a whole. The minimum effective number of doses remains an open question.

How might cost or coverage shape recommendations?

Respondents considered patient costs, insurance coverage and treatment resources. The question specified no price.

25 respondents · Survey export · 2026-11-21
  • Major influence on my recommendation7/25 (28.0%)
  • Moderate influence on my recommendation11/25 (44.0%)
  • Minor influence1/25 (4.0%)
  • Little or no influence if access and patient costs are covered6/25 (24.0%)
  • Unsure / outside my clinical role0/25 (0.0%)

How compelling did colleagues find the evidence?

Respondents rated the evidence before the meeting. One answer allowed them to defer judgment until they had reviewed the data.

25 respondents · Survey export · 2026-11-21
  • Very compelling11/25 (44.0%)
  • Moderately compelling6/25 (24.0%)
  • Promising, with important uncertainty5/25 (20.0%)
  • Not compelling at present0/25 (0.0%)
  • I need to review the data3/25 (12.0%)
Our community

Who joined the conversation?

David Miller moderated, with Kevin Emerick and Vishal Patel bringing the Teams chat into the discussion. We were pleased to welcome Dr. Sophia K. McKinley and Dr. Justin Moyers to Journal Club.

Nikhil Khushalani introduced the trial, Elizabeth Buchbinder reviewed Table 1, Andrew Knight presented Figure 1, and Adewole Adamson examined the subgroup analyses. Danielle Brazel and Karam Khaddour led the safety review. Suzanne Topalian and Vernon Sondak led the closing discussion.

SoCO organized the meeting independently and received no industry funding. Colleagues from Moderna and Merck joined the academic-led review to answer questions about trial design, treatment delivery, and analysis.

Meeting pulse

A great turnout — and people stayed

People who joined40Colleagues at SoCO’s 81st meeting
Median time with us99 minHalf the group stayed this long or longer
Stayed at least an hour90%36 of the 40 attendees
Attendance and acknowledgments

40 colleagues attended. Median attendance was 98 minutes 38 seconds. 36 stayed at least an hour.

Teams recorded camera use for 29 attendees, microphone use for 29, and hand raises for 10. In all, 32 used at least one of these features.

Attendee Affiliation
Adewole S. Adamson The University of Texas at Austin
Andrew D. Knight Mass General Brigham
Claire Verschraegen The Ohio State University
Danielle Brazel Massachusetts General Hospital
David J Savage University of New Mexico Comprehensive Cancer Center
David M. Miller Mass General Brigham
David R. Carr The Ohio State University
Dmitri Grebennik Merck & Co., Inc.
Elizabeth I. Buchbinder Mass General Brigham
Frances Collichio University of North Carolina
Howard L. Kaufman Mass Eye and Ear
Isaac Brownell National Institutes of Health
Juliane Andrade Czapla Mass General Brigham
Justin Moyers UC San Diego Health
Karam Khaddour Dana-Farber Cancer Institute
Kathryn Bollin Scripps Health
Kevin S. Emerick Mass Eye and Ear
Krista M. Rubin Mass General Brigham
Larisa Geskin Columbia University
Laureen S. Ojalvo Moderna
Li Fan Merck & Co., Inc.
Manisha Thakuria Mass General Brigham
Maya Dimitrova NYU Langone Health
Meghan J. Mooradian Mass General Brigham
Mehran Behruj Yusuf University of Alabama at Birmingham
Michael K. Wong The University of Texas MD Anderson Cancer Center
Michelle Brown Moderna
Molly Yancovitz Beth Israel Deaconess Medical Center
Nikhil Khushalani Moffitt Cancer Center
Rhoda Alani Massachusetts General Hospital
Sameer Gupta Mass Eye and Ear
Sanjay Chandrasekaran UT Southwestern Medical Center
Sarah Weiss Rutgers Cancer Institute of New Jersey
Scott Mazzeo Merck & Co., Inc.
Sophia K. McKinley Mass General Brigham
Suzanne Topalian Johns Hopkins Medicine
Toshifumi Hoki Merck & Co., Inc.
Vern Sondak Moffitt Cancer Center
Vishal Patel George Washington University
William J. Benjamin Mass Eye and Ear

SoCO thanks the colleagues who led the figure-by-figure review and the study team members who joined the discussion. Laureen Ojalvo and Michelle Brown joined from Moderna. Dmitri Grebennik, Scott Mazzeo, Toshifumi Hoki, and Li Fan joined from Merck.

Where the discussion landed

What would we take back to clinic?

The question changes depending on when we see the patient. For someone already planning adjuvant pembrolizumab, INTerpath-001 helps quantify the added benefit of intismeran at two years. For someone considering surveillance, the conversation starts with their risk of recurrence after surgery alone. And for someone we meet before surgery, there’s an earlier question: should treatment begin before the operation?

Building on SoCO’s Art of Authorship workshop, David Miller invited participants interested in developing a Perspective on the Science to reach out with the contribution they would like to make.

Society of Cutaneous Oncology · Journal Club · November 20, 2026

More SoCO Journal Clubs

© Society of Cutaneous Oncology

 
  • Journal of Cutaneous Oncology

  • SoCO Journal Club

  • Community Highlights

  • History